Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has wreaked havoc worldwide and has claimed innumerable lives till date. The clinical spectrum of this disease may range from mild self-limiting flu-like symptoms to the severe form of illness like severe pneumonia and acute respiratory distress syndrome (ARDS) with high morbidity and mortality. With better disease understanding and improved diagnostic techniques, a large number of cases are being detected with florid extrapulmonary manifestations and complications [1,2]. Those extrapulmonary manifestations of the coronavirus disease 2019 (COVID-19) range from renal and gastrointestinal to hepatic, cardiac, haematological and neurological dysfunction. A recent study from Wuhan showed that more than one third of admitted patients had some form of neurological symptoms [3]. The neurological features of this infection include anosmia, dysgeusia, dizziness, headache, cerebrovascular accident, acute encephalitis, acute transverse myelitis (ATM) and Guillain-Barre syndrome (GBS) [4,5]. We report a case of GBS secondary to COVID-19, complicated by treatment related fluctuation (TRF). Thorough search of the PubMed and Medline database revealed no such similar cases in English language literature.

2. Case report

A 35-year-old gentleman presented to our institution on 1st January 2021 with the complaint of diffuse back pain and weakness of both lower limbs which started from the distal legs over last 2 days. Within 1 week he became bedbound with quadriplegia, dysphagia and bilateral lower motor neuron type facial nerve palsy. Neurological examination was significant for bilateral lower motor neuron type facial nerve palsy, reduced tone with symmetrical weakness of 2/5 on the Medical Research Council (MRC) Power Grading Scale in all 4 limbs with involvement of neck and trunk muscles. His deep tendon reflexes were absent. However, he had no sensory or bladder involvement. His Eramus GBS respiratory insufficiency score was 5 and he was shifted to ICU. His past history was notable for a high grade fever with loss of taste and smell sensation three weeks prior to this presentation. At that time, on 11th December 2020, his nasopharyngeal swab was positive for SARS-CoV-2 (COVID-19) RNA, done by RT-PCR (Reverse Transcription...
Polymerase Chain Reaction) method. His chest X-ray at that time did not reveal any evidence of consolidation, patchy or lobar infiltrates or ground-glass opacity. His complete blood count, liver and renal function profile, electrolytes, thyroid function test and clotting functions were all within the normal range except raised C-reactive protein (25 mg/L). He was in home isolation during that time, did not develop any respiratory distress throughout his illness and over next 1 week became afebrile.

Antinuclear antibody, extractable nuclear antigen (ENA) panel, antineutrophil cytoplasmic antibodies, syphilis serology and blood-borne virus screen (HIV, hepatitis B and hepatitis C) were negative. Cerebrospinal fluid analysis at this juncture demonstrated cytological dissociation. Nerve conduction studies revealed prolonged distal motor latencies and reduced compound motor action potential and conduction velocity in motor nerves in the upper and lower limbs. Motor action potentials showed marked dispersion in their morphology and conduction block (Figs. 1 and 2). F-waves were not obtained from the median, ulnar, common peroneal and tibial nerves. Sensory nerve conduction studies showed no amplitude in median and ulnar nerves and were within normal limits for both sural nerves. These results fulfill the electrodiagnostic criteria for acute inflammatory demyelinating polyneuropathy/GBS. The details of the nerve conduction study of the patient have been summarized in Table 1.

Treatment with intravenous immunoglobulin at 2 g/kg dose initiated on day 8 of the illness and continued for 5 days and his weakness improved, 4/5 and 3/5 MRC grade in upper and lower limbs respectively with improvement of bulbar and facial palsy and he was planned for discharge.

On 18th January, his limb power started to worsen again. He developed respiratory distress and was put on ventilator as vital capacity went down to 700 ml. Further intravenous immunoglobulin treatment was commenced. His repeat high resolution computed tomography scan of thorax did not reveal any abnormality. He was gradually weaned off ventilator and he became ambulatory after 35 days. The fluctuation of the motor power according to the Medical Research Council (MRC) Power Grading Scale over 5 weeks has been summarized in Table 2.

3. Discussion

In addition to the characteristic respiratory symptoms, reports are emerging of a wide-spectrum of neurological manifestations of COVID-19, which range from milder symptoms such as anosmia to severe complications such as stroke and encephalitis. Guillain-Barre syndrome (GBS) is an immune-mediated neurological disorder, where the peripheral nerves are being affected by the immune system and there is a preceding history of an upper respiratory infection or gastroenteritis in most of the cases [6]. Different mechanisms have been proposed to explain the pathogenesis of GBS following COVID-19. The most accepted mechanism is the formation of antibodies against surface glycoproteins of the pathogen which may damage peripheral nerves due to a similar native protein structures (molecular mimicry) [7]. Other proposed theories include hyperinflammation as a consequence of cytokine storm in patients with COVID-19 [8,9]. Since the outbreak of the pandemic, the incidence of GBS has increased [10]. There have been many reports describing the association between SARS-CoV-2 infection and GBS [11,12].

Treatment related fluctuation (TRF) is defined as at least one grade increment in the GBS disability scale after completion of immunotherapy in the form of immunoglobulin or plasmapheresis followed by at least one grade worsening of the disability scale within the first two months after disease onset [13]. Two important differentials of TRF are recurrent GBS and acute onset chronic

Fig. 1. Motor nerve conduction study of left ulnar nerve showing temporal dispersion.

Fig. 2. Motor nerve conduction study of right median nerve showing conduction block.
inflammatory demyelinating polyradiculoneuropathy (A-CIDP), however both possibilities are negated as the disease improved within first 2 weeks, worsened again from 18th day followed by improvement and no further worsening documented over next 8 weeks of onset of initial weakness. A diagnosis of A-CIDP should be thought of when a patient of GBS deteriorates again after 8 weeks from the onset or when deterioration takes place for three times or more. According to a Dutch study, A-CIDP patients rarely develop cranial nerve dysfunction and very rarely need artificial ventilation [13]. TRF in this patient can occur due to prolonged immune response as the disease recurred after the therapeutic effect of immunoglobulin diminished off. The same study also reported almost one out of every ten GBS patients suffer from TRF and the disease almost never show secondary fluctuations beyond 8 weeks. Many aspects of our patient acted as predictors of TRF. Romano et al. mentioned that comorbidities increase chance of TRF but our patient had none [14]. Significant proximal muscle involvement, cranial nerve palsy, no antecedent diarrhea and absence of anti-GM1 antibodies are important predictors of TRF in GBS, all of them were present in our patient [9]. TRF patients have non-favorable outcome compared to non TRF patients, which is not true in our case [13].

The important mechanisms of action of immunoglobulins are complement inactivation, antibody neutralization, inhibition of cytokines and saturation of Fc receptors on macrophages [15]. Early worsening after treatment followed by improvement on repeat treatment can be due to sustained production of antibodies and rebound immunological response. Many studies contradict this idea as antibody titres do not correlate with clinical worsening [14]. However, clinical scenario of our patient suggests the first explanation.

Worldwide many cases of post COVID-19 GBS are reported, however this is probably the first case reported with TRF and patient was successfully treated with reinstitution of immunoglobulin therapy; came out of ventilation and became ambulatory again.

### Contributorship statement

SG and AC contributed to conception, initial drafting of manuscript, critical revision of content and final approval of manuscript. SG, BKR and AP contributed to patient management, conception, critical revision of content and final approval of manuscript. Authors have testified that all persons designated as authors qualify for authorship and have checked the article for plagiarism. All authors had substantial contributions to the conception or design of the work; the acquisition, analysis, or interpretation of the data; drafting the work or revising it critically for important intellectual content, and final approval of the version to be published. All are in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

### Table 1

| Nerve        | DML (ms) | CMAP (mv) | Area   | CV (m/s) |
|--------------|----------|-----------|--------|----------|
| Right Median | 6.56     | 4.7 (Wrist) | 13.1 (Wrist) | 28.81    |
|              | 1.7 (Elbow) | 6.2 (Elbow) |
|              | 1.1 (Erbs) | 4.3 (Erbs) |
| Left Median  | 6.46     | 2.3 (Wrist) | 7.8 (Wrist) | 30.57    |
|              | 1.2 (Elbow) | 4.1 (Elbow) |
|              | 0.7 (Erbs) | 2.7 (Erbs) |
| Right Ulnar  | 5.94     | 1.1 (Wrist) | 6.5 (Wrist) | 24.01    |
|              | 1.0 (Elbow) | 5.5 (Elbow) |
|              | 0.9 (Erbs) | 3.8 (Erbs) |
| Left Ulnar   | 5.42     | 1.2 (Wrist) | 6.6 (Wrist) | 24.55    |
|              | 0.3 (Elbow) | 1.4 (Elbow) |
|              | 0.22 (Erbs) | 1.2 (Erbs) |
| Right Tibial | 9.06     | 1.4 (Ankle) | 6.0 (Ankle) | 20.48    |
|              | 0.3 (Knee) | 1.2 (Knee) |
| Left Tibial  | 7.50     | 0.6 (Ankle) | 2.5 (Ankle) | 21.82    |
|              | 0.5 (Knee) | 1.3 (Knee) |
| Right common peroneal | 5.52 | 1.9 (Ankle) | 7.9 (Ankle) | Could not be calculated |
| Left common peroneal | 5.94 | 1.2 (Ankle) | 4.2 (Ankle) | Could not be calculated |

| Nerve                     | DSL (ms) | SNAP (μv) | Area |
|---------------------------|----------|-----------|------|
| Right Median              | NR       | NR        | NR   |
| Left Median               | NR       | NR        | NR   |
| Right Median              | NR       | NR        | NR   |
| Left Median               | NR       | NR        | NR   |
| Right Ulnar               | 2.08     | 21.8      | 6.5  |
| Left Ulnar                | 2.29     | 17.9      | 7.7  |

CMAP = compound motor action potential, CV = conduction velocity, DML = distal motor latency, DSL = distal sensory latency, SNAP = sensory nerve action potential.

### Table 2

Fluctuations of motor power over 5 weeks.

| Medical Research Council (MRC) Power Grading Scale | Day 7 | Day 14 | Day 21 | Day32 |
|--------------------------------------------------|------|-------|-------|-------|
| Shoulder abduction                               | 2    | 4     | 2     | 4     |
| Elbow flexion                                    | 2    | 4     | 2     | 4     |
| Wrist extension                                  | 2    | 3     | 2     | 4     |
| Hip flexion                                      | 2    | 3     | 2     | 4     |
| Knee extension                                   | 2    | 3     | 2     | 4     |
| Ankle dorsiflexia                                | 2    | 3     | 1     | 4     |
Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not for-profit sectors.

Consent

*** An informed written consent was obtained from the patient after full explanation regarding his images being published for academic interest. The patient did not have any objection regarding use of his images and gave due permission to use them.

Declaration of competing interest

We do hereby declare that No author of this paper has a conflict of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included in this manuscript.

Acknowledgement

Nil.

References

[1] Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020 Jul;26(7):1017–22. https://doi.org/10.1038/s41591-020-0968-3. Epub 2020 Jul 10. PMID: 32651579.

[2] Chandra A, Chakraborty U, Ghosh S, Dasgupta S. Anticoagulation in COVID-19: current concepts and controversies. Postgrad Med 2021 Apr 13. https://doi.org/10.1136/postgradmedj-2021-139923. Epub ahead of print. PMID: 33850011.

[3] Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77(6):683–90. https://doi.org/10.1001/jamaneurol.2020.1127.

[4] Whittaker A, Anson M, Harky A. Neurological Manifestations of COVID-19: a systematic review and current update. Acta Neurol Scand 2020 Jul;142(1):14–22. https://doi.org/10.1111/ane.13266. Epub 2020 Jun 21. PMID: 32412088; PMCID: PMC7273036.

[5] Chakraborty U, Chandra A, Ray AK, Biswas P. COVID-19-associated acute transverse myelitis: a rare entity. BMJ Case Rep 2020 Aug 25;13(8):e238668. https://doi.org/10.1136/bcr-2020-238668. PMID: 32843475; PMCID: PMC7449353.

[6] Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam Physician 2013 Feb 1;87(3):191–7. PMID: 23441763.

[7] Lucchesi G, Ploeo A. SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism. Cell Stress Chaperones 2020 Sep;25(5):731–5. https://doi.org/10.1007/s12192-020-01145-6. Epub 2020 Jul 29. PMID: 32729001; PMCID: PMC7387840.

[8] Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020 May;19(5):383–4. https://doi.org/10.1016/S1474-4422(20)30109-5. Epub 2020 Apr 1. PMID: 32246917; PMCID: PMC7176927.

[9] Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020;382:2574–6.

[10] Finsterer J, Scorza FA. Guillain-Barré syndrome in 220 patients with COVID-19. Egypt J Neurol Psychiatr Neurosurg 2021;57(1):55. https://doi.org/10.1186/s41983-021-00310-7. Epub 2021 May 4. PMID: 33967575; PMCID: PMC8094972.

[11] Caress JB, Castoro BJ, Simmons Z, Scelsa SN, Lewis RA, Ablawat A, Narayanawami P. COVID-19-associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve 2020 Oct;62(4):485–91. https://doi.org/10.1002/mus.27024. Epub 2020 Aug 11. PMID: 32678460; PMCID: PMC7405390.

[12] Zuberbühler P, Conti ME, León-Cejas L, Maximiliano-González F, Bonardo P, Miquelin A, et al. Guillain-Barré syndrome associated to COVID-19 infection: a review of published case reports. PMID: 33710610 Rev Neurol 2021 Mar 16;72(6):203–12. https://doi.org/10.33588/nn.7206.2020487. English, Spanish.

[13] Visser LH, van der Meché FG, Meulstee J, van Doorn PA. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group. J Neurol Neurosurg Psychiatry 1998;64:242–4.

[14] Romano JC, Rotta FT, Potter P, Rosenfeld V, Santibanez R, Rocha B, et al. Re-lapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve 1998;21:1327–30.

[15] Kuwabara S. Guillain-barré syndrome: epidemiology, pathophysiology and management. Drugs 2004;64:597–610.